Graeff H - Search Results

1

Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.

Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H. Schmitt M, et al. Among authors: graeff h. Biomed Biochim Acta. 1991;50(4-6):731-41. Biomed Biochim Acta. 1991. PMID: 1801751

2

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Jänicke F, Schmitt M, Graeff H. Jänicke F, et al. Among authors: graeff h. Semin Thromb Hemost. 1991 Jul;17(3):303-12. doi: 10.1055/s-2007-1002624. Semin Thromb Hemost. 1991. PMID: 1796300 No abstract available.

3

Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.

Schmitt M, Kanayama N, Jänicke F, Hafter R, Graeff H. Schmitt M, et al. Among authors: graeff h. Adv Exp Med Biol. 1991;297:111-28. doi: 10.1007/978-1-4899-3629-5_10. Adv Exp Med Biol. 1991. PMID: 1837419

4

Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).

Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H. Kobayashi H, et al. Among authors: graeff h. J Biol Chem. 1991 Mar 15;266(8):5147-52. J Biol Chem. 1991. PMID: 1900515 Free article.

5

Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.

Schmitt M, Jänicke F, Graeff H. Schmitt M, et al. Among authors: graeff h. Blood Coagul Fibrinolysis. 1990 Dec;1(6):695-702. Blood Coagul Fibrinolysis. 1990. PMID: 2133250

6

Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).

Schmitt M, Kanayama N, Henschen A, Hollrieder A, Hafter R, Gulba D, Jänicke F, Graeff H. Schmitt M, et al. Among authors: graeff h. FEBS Lett. 1989 Sep 11;255(1):83-8. doi: 10.1016/0014-5793(89)81065-8. FEBS Lett. 1989. PMID: 2529137 Free article.

7

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Schmalfeldt B, et al. Among authors: graeff h. Cancer Res. 1995 Sep 15;55(18):3958-63. Cancer Res. 1995. PMID: 7664262

8

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Kuhn W, et al. Among authors: graeff h. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9. doi: 10.1006/gyno.1994.1313. Gynecol Oncol. 1994. PMID: 7835780

9

Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.

Wilhelm S, Wilhelm O, Schmitt M, Graeff H. Wilhelm S, et al. Among authors: graeff h. Biol Chem Hoppe Seyler. 1994 Sep;375(9):603-8. doi: 10.1515/bchm3.1994.375.9.603. Biol Chem Hoppe Seyler. 1994. PMID: 7840902

10

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Jänicke F, et al. Among authors: graeff h. Cancer Res. 1994 May 15;54(10):2527-30. Cancer Res. 1994. PMID: 8168072

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

219 results

Search Page

Filters